Lunit Reports Q1 2026 Revenue Growth, Completes Rights Offering and Stock Dividend
Lunit reported consolidated Q1 2026 revenue of 23,952 million KRW (up 25% YoY) and operating loss of 13,593 million KRW (improved from 20,802 million loss a year ago).
Net loss of 17,810 million KRW (vs net profit of 1,892 million in Q1 2025), mainly due to lower fair value gains on convertible bond derivatives.
In April 2026, completed a rights offering of 7,906,816 shares (approx. 211.5 billion KRW). A 1:1 stock dividend is scheduled in May.
Debt ratio rose to 212% (from 169% at year-end 2025). Cash and equivalents increased to 38.8 billion KRW (from 14.1 billion).
Early redemption of 16.19 billion KRW face value of Series 1 CB (total 18.68 billion KRW including 8% compound interest) paid on May 4, 2026.
Cancer Screening segment revenue of 22,274 million KRW (+22% YoY); Oncology segment revenue of 1,678 million KRW (+90% YoY).
R&D expenses of 6.8 billion KRW (28.4% of revenue). Collaborating with 15 of the top 20 global pharmaceutical companies.